To validate our preclinical findings, we tested whether activation of IFN signalling also occurred in patients given ICB therapy, using single cell RNAseq data from a cohort of treatment naïve breast cancer patients, subsequently treated with anti-PD-1 and with paired T cell expansion data25. This evidence concerns the gene IFNA1 and breast carcinoma.